68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Rauscher, Isabel; Maurer, Tobias; Fendler, Wolfgang; Sommer, Wieland; Schwaiger, Markus; Eiber, Matthias
• Is Part Of: Cancer imaging. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 10
• Publication Date: 2016-12
• Subjects: Prostate cancer -- Prostate specific membrane antigen -- Positron emission tomography; Cancer -- Imaging -- Periodicals; 616.994075405
• DOI: 10.1186/s40644-016-0072-6
• Languages: English
• ISSNs: 1740-5025

Abstract

Abstract Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with68 Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with68 Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of68 Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.